- Home
- VENU vs ALLO Comparison
VENU vs ALLO Comparison
Compare VENU & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VENU
- ALLO
- Stock Information
- Founded
- VENU 2017
- ALLO 2017
- Country
- VENU United States
- ALLO United States
- Employees
- VENU N/A
- ALLO 361
- Industry
- VENU
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VENU
- ALLO Health Care
- Exchange
- VENU NYSE
- ALLO Nasdaq
- Market Cap
- VENU 313.2M
- ALLO 371.8M
- IPO Year
- VENU 2024
- ALLO 2018
- Fundamental
- Price
- VENU $7.90
- ALLO $1.17
- Analyst Decision
- VENU
- ALLO Strong Buy
- Analyst Count
- VENU 0
- ALLO 10
- Target Price
- VENU N/A
- ALLO $9.66
- AVG Volume (30 Days)
- VENU 20.0K
- ALLO 2.9M
- Earning Date
- VENU 05-15-2025
- ALLO 05-13-2025
- Dividend Yield
- VENU N/A
- ALLO N/A
- EPS Growth
- VENU N/A
- ALLO N/A
- EPS
- VENU N/A
- ALLO N/A
- Revenue
- VENU $17,834,383.00
- ALLO $22,000.00
- Revenue This Year
- VENU $91.00
- ALLO N/A
- Revenue Next Year
- VENU $422.18
- ALLO $9.07
- P/E Ratio
- VENU N/A
- ALLO N/A
- Revenue Growth
- VENU 41.57
- ALLO N/A
- 52 Week Low
- VENU $7.05
- ALLO $1.09
- 52 Week High
- VENU $11.15
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- VENU N/A
- ALLO 38.89
- Support Level
- VENU N/A
- ALLO $1.09
- Resistance Level
- VENU N/A
- ALLO $1.78
- Average True Range (ATR)
- VENU 0.00
- ALLO 0.14
- MACD
- VENU 0.00
- ALLO -0.03
- Stochastic Oscillator
- VENU 0.00
- ALLO 27.46
About VENU VENU HOLDING CORPORATION
Venu Holding Corp is an entertainment and hospitality holding company based in Colorado Springs, Colorado. It designs, develops, owns, and operates up-scale music venues, outdoor amphitheaters, and full-service restaurants and bars where music, dining, and luxury experiences converge.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.